Company Interview / Ebola risk drives urgency for this small cap

Key points:

Island Pharmaceuticals (ASX:ILA) secures an additional US patent for broad-spectrum antiviral GalidesivirNo approved treatments currently exist for Marburg, highlighting significant unmet needClinical approval path leverages animal efficacy studies under the US FDA’s Animal RuleCompany maintains a strong cash position to support ongoing development steps

Island Pharmaceuticals (ASX:ILA) has secured an additional US patent for its antiviral molecule, Galidesivir, with potential application against lethal viruses such as Ebola and Marburg. David Foster states that this new protection strengthens the company’s already robust patent portfolio, acquired from BioCryst Pharmaceuticals, and provides broad claims over the use of Galidesivir against highly dangerous viruses. He highlights the pressing need for new treatments as Marburg currently has no approved vaccines or antiviral drugs available on the market, while options for Ebola remain limited.

Foster points out that both Ebola and Marburg are recognised by the US government as significant threats to public health, with concerns heightened by the possibility of their weaponisation. Island Pharmaceuticals' approach to clinical trials leverages the US FDA’s Animal Rule, allowing drug approval based on animal efficacy data when human trials are unethical or unsafe. Foster notes two phase one clinical trials are already complete, underpinning the safety profile of the candidate. Preparations are underway for an additional efficacy study in non-human primates.

The company’s antiviral asset also demonstrates activity against a range of viruses, including Zika, MERS, SARS, COVID-19, and measles, supporting its broad-spectrum potential. Foster indicates the business is well-funded, following a conservative spend and a strong cash position at the end of Q1 last year.